Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tarsus Pharmaceuticals, Inc.

49.71
-0.2900-0.58%
Volume:436.19K
Turnover:21.56M
Market Cap:2.07B
PE:-16.18
High:50.50
Open:50.10
Low:48.02
Close:50.00
Loading ...

Company Profile

Company Name:
Tarsus Pharmaceuticals, Inc.
Exchange:
NASDAQ
Establishment Date:
2016
Employees:
323
Office Location:
15440 Laguna Canyon Road,Suite 160,Irvine,California,United States
Zip Code:
92618
Fax:
- -
Introduction:
Tarsus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Directors

Name
Position
Bobak Azamian
President, Chief Executive Officer and Director
Michael Ackermann
Chairperson of the Board
Andrew Goldberg
Director
Bhaskar Chaudhuri
Director
Jason Tester
Director
William J. Link
Director

Shareholders

Name
Position
Bobak Azamian
President, Chief Executive Officer and Director
Seshadri Neervannan
Chief Operating Officer
Leo M. Greenstein
Chief Financial Officer
Aziz Mottiwala
Chief Commercial Officer
Mark Holdbrook
Vice President, Clinical Affairs